Naomi Schlesinger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3141440/publications.pdf

Version: 2024-02-01

126907 128289 3,971 111 33 60 citations g-index h-index papers 121 121 121 3473 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Annals of the Rheumatic Diseases, 2012, 71, 1839-1848.	0.9	289
2	Canakinumab for the treatment of acute flares in difficultâ€toâ€treat gouty arthritis: Results of a multicenter, phase II, doseâ€ranging study. Arthritis and Rheumatism, 2010, 62, 3064-3076.	6.7	264
3	Management of Acute and Chronic Gouty Arthritis. Drugs, 2004, 64, 2399-2416.	10.9	187
4	Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Annals of the Rheumatic Diseases, 2011, 70, 1264-1271.	0.9	187
5	Outcome Domains for Studies of Acute and Chronic Gout. Journal of Rheumatology, 2009, 36, 2342-2345.	2.0	147
6	The pathogenesis of bone erosions in gouty arthritis. Annals of the Rheumatic Diseases, 2010, 69, 1907-1912.	0.9	134
7	Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved. Rheumatology International, 2010, 30, 495-503.	3.0	131
8	Uric acid in Parkinson's disease. Movement Disorders, 2008, 23, 1653-1657.	3.9	112
9	Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Research and Therapy, 2011, 13, R53.	3.5	105
10	Dietary Factors and Hyperuricaemia. Current Pharmaceutical Design, 2005, 11, 4133-4138.	1.9	103
11	Serum Urate During Acute Gout. Journal of Rheumatology, 2009, 36, 1287-1289.	2.0	93
12	Local ice therapy during bouts of acute gouty arthritis. Journal of Rheumatology, 2002, 29, 331-4.	2.0	90
13	Colchicine in COVID-19: an Old Drug, New Use. Current Pharmacology Reports, 2020, 6, 137-145.	3.0	88
14	Gastrointestinal Involvement in Polyarteritis Nodosa. Clinical Gastroenterology and Hepatology, 2008, 6, 960-966.	4.4	84
15	Pegloticase. Nature Reviews Drug Discovery, 2011, 10, 17-18.	46.4	81
16	Colchicine for acute gout. The Cochrane Library, 2014, , CD006190.	2.8	77
17	Gout, Hyperuricemia, and Crystalâ€Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. Arthritis Care and Research, 2019, 71, 427-434.	3.4	73
18	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Annals of the Rheumatic Diseases, 2019, 78, 1592-1600.	0.9	72

#	Article	IF	Citations
19	Chronopharmacology of glucocorticoids. Advanced Drug Delivery Reviews, 2019, 151-152, 245-261.	13.7	68
20	Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19. Journal of Clinical Medicine, 2020, 9, 2961.	2.4	65
21	Diagnosis of gout: clinical, laboratory, and radiologic findings. American Journal of Managed Care, 2005, 11, S443-50; quiz S465-8.	1.1	59
22	Progress in Measurement Instruments for Acute and Chronic Gout Studies. Journal of Rheumatology, 2009, 36, 2346-2355.	2.0	53
23	Gout: can management be improved?. Current Opinion in Rheumatology, 2001, 13, 240-244.	4.3	52
24	Outcome measures for acute and chronic gout. Journal of Rheumatology, 2005, 32, 2452-5.	2.0	52
25	Anti-Interleukin-1 Therapy in the Management of Gout. Current Rheumatology Reports, 2014, 16, 398.	4.7	51
26	Colchicine for acute gout. , 2006, , CD006190.		50
27	Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. Arthritis Care and Research, 2016, 68, 667-672.	3.4	48
28	Treatment of acute gout in hospitalized patients. Journal of Rheumatology, 2007, 34, 1566-8.	2.0	47
29	Difficult-to-Treat Gouty Arthritis. Drugs, 2011, 71, 1413-1439.	10.9	43
30	A survey of current evaluation and treatment of gout. Journal of Rheumatology, 2006, 33, 2050-2.	2.0	42
31	Sex differences in gout characteristics: tailoring care for women and men. BMC Musculoskeletal Disorders, 2017, 18, 108.	1.9	41
32	Diagnosing and Treating Gout: A Review to Aid Primary Care Physicians. Postgraduate Medicine, 2010, 122, 157-161.	2.0	40
33	Non-steroidal anti-inflammatory drugs for acute gout. The Cochrane Library, 2014, , CD010120.	2.8	40
34	Serum uric acid in acute gout. Annals of the Rheumatic Diseases, 1998, 57, 443-444.	0.9	38
35	The role of the hypothalamic-pituitary-adrenal axis in modulating seasonal changes in immunity. Physiological Genomics, 2016, 48, 719-738.	2.3	36
36	Gout – what are the treatment options?. Expert Opinion on Pharmacotherapy, 2009, 10, 1319-1328.	1.8	35

#	Article	IF	CITATIONS
37	Tuberculosis of the Spine. Journal of Clinical Rheumatology, 2005, 11, 17-20.	0.9	31
38	Overview of the Management of Acute Gout and the Role of Adrenocorticotropic Hormone. Drugs, 2008, 68, 407-415.	10.9	30
39	Beyond urate lowering: Analgesic and anti-inflammatory properties of allopurinol. Seminars in Arthritis and Rheumatism, 2020, 50, 444-450.	3.4	28
40	Outcome evaluations in gout. Journal of Rheumatology, 2007, 34, 1381-5.	2.0	28
41	How well have diagnostic tests and therapies for gout been evaluated?. Current Opinion in Rheumatology, 1999, 11, 441-445.	4.3	27
42	Response to Application of Ice May Help Differentiate Between Gouty Arthritis and Other Inflammatory Arthritides. Journal of Clinical Rheumatology, 2006, 12, 275-276.	0.9	26
43	OMERACT Endorsement of Measures of Outcome for Studies of Acute Gout. Journal of Rheumatology, 2014, 41, 569-573.	2.0	26
44	Erectile Dysfunction Is Common among Patients with Gout. Journal of Rheumatology, 2015, 42, 1893-1897.	2.0	26
45	New Agents for the Treatment of Gout and Hyperuricemia: Febuxostat, Puricase, and Beyond. Current Rheumatology Reports, 2010, 12, 130-134.	4.7	25
46	Treatment of Chronic Gouty Arthritis: It Is Not Just About Urate-Lowering Therapy. Seminars in Arthritis and Rheumatism, 2012, 42, 155-165.	3.4	25
47	Beyond Joints: a Review of Ocular Abnormalities in Gout and Hyperuricemia. Current Rheumatology Reports, 2016, 18, 37.	4.7	25
48	Pilot Studies of Cherry Juice Concentrate for Gout Flare Prophylaxis. Journal of Arthritis, 2012, 01, .	0.3	24
49	Pegloticase treatment of chronic refractory gout: Update on efficacy and safety. Seminars in Arthritis and Rheumatism, 2020, 50, S31-S38.	3.4	24
50	Daily Moderate Exercise Is Beneficial and Social Stress Is Detrimental to Disease Pathology in Murine Lupus Nephritis. Frontiers in Physiology, 2017, 8, 236.	2.8	21
51	Seasonal variation of rheumatic diseases. Discovery Medicine, 2005, 5, 64-9.	0.5	21
52	Canakinumab in gout. Expert Opinion on Biological Therapy, 2012, 12, 1265-1275.	3.1	19
53	Treatment of Acute Gout. Rheumatic Disease Clinics of North America, 2014, 40, 329-341.	1.9	19
54	Use of dual-energy computed tomography for the evaluation of calcinosis in patients with systemic sclerosis. Clinical Rheumatology, 2015, 34, 1557-1561.	2.2	19

#	Article	IF	CITATIONS
55	The safety of treatment options available for gout. Expert Opinion on Drug Safety, 2017, 16, 429-436.	2.4	19
56	Acute Gouty Arthritis Is Seasonal. Journal of Clinical Rheumatology, 2005, 11, 240-242.	0.9	16
57	Intra-articular glucocorticoids for acute gout. The Cochrane Library, 2013, , CD009920.	2.8	16
58	New and Pipeline Drugs for Gout. Current Rheumatology Reports, 2016, 18, 32.	4.7	15
59	Gout and the Risk of Incident Erectile Dysfunction: A Body Mass Index-matched Population-based Study. Journal of Rheumatology, 2018, 45, 1192-1197.	2.0	15
60	Seasonal variation of lupus nephritis: high prevalence of class V lupus nephritis during the winter and spring. Journal of Rheumatology, 2005, 32, 1053-7.	2.0	15
61	The Potential of Circadian Realignment in Rheumatoid Arthritis. Critical Reviews in Biomedical Engineering, 2016, 44, 177-191.	0.9	14
62	Calcinosis in scleroderma made crystal clear. Current Opinion in Rheumatology, 2019, 31, 589-594.	4.3	13
63	The Hepato-Hypothalamic-Pituitary-Adrenal-Renal Axis: Mathematical Modeling of Cortisol's Production, Metabolism, and Seasonal Variation. Journal of Biological Rhythms, 2017, 32, 469-484.	2.6	12
64	Response to the 2020 American College of Rheumatology Guideline for the Management of Gout: Comment onthe Article by FitzGerald et al. Arthritis Care and Research, 2020, 72, 1506-1507.	3.4	12
65	Beyond Medical Treatment: Surgical Treatment of Gout. Current Rheumatology Reports, 2021, 23, 1.	4.7	12
66	Colchicine for acute gout. The Cochrane Library, 2021, 2021, CD006190.	2.8	12
67	Previously Reported Prior Studies of Cherry Juice Concentrate for Gout Flare Prophylaxis: Comment on the Article by Zhang et al. Arthritis and Rheumatism, 2013, 65, 1135-1136.	6.7	11
68	Inorganic pyrophosphate is reduced in patients with systemic sclerosis. Rheumatology, 2022, 61, 1158-1165.	1.9	11
69	Management of Gout in the United States: A Claimsâ€based Analysis. ACR Open Rheumatology, 2020, 2, 180-187.	2.1	10
70	Update on gout. Arthritis and Rheumatism, 2002, 47, 563-565.	6.7	9
71	Lytic Bone Lesions as a Prominent Feature in Waldenstrom's Macroglobulinemia. Journal of Clinical Rheumatology, 2000, 6, 150-153.	0.9	8
72	Reassessing the safety of intravenous and compounded injectable colchicine in acute gout treatment. Expert Opinion on Drug Safety, 2007, 6, 625-629.	2.4	8

#	Article	IF	Citations
73	Febuxostat, a novel drug for the treatment of hyperuricemia of gout. Future Rheumatology, 2008, 3, 421-427.	0.2	8
74	Diagnosis and Treatment of Acute Gout at a University Hospital Emergency Department. Open Rheumatology Journal, 2015, 9, 21-26.	0.2	8
75	Gout Prophylaxis Evaluated According to the 2012 American College of Rheumatology Guidelines: Analysis from the CORRONA Gout Registry. Journal of Rheumatology, 2016, 43, 924-930.	2.0	8
76	Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials. Clinical Rheumatology, 2021, 40, 683-692.	2.2	8
77	Adherence to the 2012 American College of Rheumatology (ACR) Guidelines for Management of Gout: A Survey of Brazilian Rheumatologists. PLoS ONE, 2015, 10, e0135805.	2.5	8
78	Dual-energy Computed Tomography for the Evaluation of Calcinosis in Systemic Sclerosis. Journal of Rheumatology, 2015, 42, 345-346.	2.0	7
79	Chronic tophaceous gout as the first manifestation of gout in two cases and a review of the literature. Seminars in Arthritis and Rheumatism, 2018, 47, 843-848.	3.4	7
80	Evaluation of Proposed Criteria for Remission and Evidenceâ€Based Development of Criteria for Complete Response in Patients With Chronic Refractory Gout. ACR Open Rheumatology, 2019, 1, 236-243.	2.1	7
81	Fungal Bursitis. Journal of Clinical Rheumatology, 1995, 1, 232-235.	0.9	6
82	Beyond Arthritis: Understanding the Influence of Gout on Erectile Function: A Systematic Review. Urology, 2021, 153, 19-27.	1.0	6
83	Enhancing the Response Rate to Recombinant Uricases in Patients with Gout. BioDrugs, 2022, 36, 95-103.	4.6	6
84	Can ultrasonography make identification of asymptomatic hyperuricemic individuals at risk for developing gouty arthritis more crystal clear?. Arthritis Research and Therapy, 2011, 13, 107.	3.5	4
85	Did Michelangelo Have Gout?. Journal of Clinical Rheumatology, 2015, 21, 364-367.	0.9	4
86	How well have diagnostic tests and therapies for gout been evaluated? Current Opinion in Orthopaedics, 2000, 11, 71-76.	0.3	3
87	Contentious Issues in Gout Management: The Story so Far. Open Access Rheumatology: Research and Reviews, 2021, Volume 13, 111-122.	1.6	3
88	Dr. Schlesinger replies. Journal of Rheumatology, 2016, 43, 1617.2-1617.	2.0	2
89	Relationship of Interleukin- $\hat{\Pi}^2$ Blockade With Incident Gout and Serum Uric Acid Levels. Annals of Internal Medicine, 2019, 170, 737.	3.9	2
90	Development of a multivariable improvement measure for gout. Arthritis Research and Therapy, 2020, 22, 164.	3.5	2

#	Article	IF	CITATIONS
91	Treatment of Acute Gout Flares in the Emergency Department: Comment on the Article by Dalal et al. Arthritis Care and Research, 2020, 72, 1663-1663.	3.4	2
92	Treatment of Acute Gout Flares in the Emergency Department: Prescribing Patterns and Revisit Rates. Annals of Pharmacotherapy, 2022, 56, 422-429.	1.9	2
93	Clues to pathogenesis of fibromyalgia in patients with sickle cell disease. Journal of Rheumatology, 2004, 31, 598-600.	2.0	2
94	Numb From Rejection: Academic Publishing Is Not for the Faint-hearted. Journal of Rheumatology, 2022, 49, 540-541.	2.0	2
95	Bursitis in Acute Bacterial Endocarditis. Journal of Clinical Rheumatology, 1997, 3, 119.	0.9	1
96	Adrenocorticotropic hormone for acute gout. The Cochrane Library, 0, , .	2.8	1
97	Tophaceous Pustule-like Rash in a Patient with Gout. Journal of Rheumatology, 2012, 39, 194-195.	2.0	1
98	New recommendations highlight the need for more research. Nature Reviews Rheumatology, 2016, 12, 628-630.	8.0	1
99	Current Pharmacological Treatments ofÂChronic Gout. , 2019, , 169-177.		1
100	Does seasonality of the microbiota contribute to the seasonality of acute gout flare?. Clinical and Experimental Rheumatology, 2022, , .	0.8	1
101	The relationship between metabolic syndrome severity and the risk of mortality in gout patients: a population-based study Clinical and Experimental Rheumatology, 2022, , .	0.8	1
102	Identification of Gulf War Syndrome: Methodological Issues and Medical Illnesses. JAMA - Journal of the American Medical Association, 1997, 278, 383.	7.4	0
103	Febuxostat. Drugs, 2008, 68, 1875-1876.	10.9	0
104	In Defense of Research into the Crystal Induced Arthropathies. Journal of Rheumatology, 2008, 35, 2278-2279.	2.0	0
105	The role of ultrasonography in imaging of gouty arthritis. Imaging in Medicine, 2011, 3, 609-611.	0.0	0
106	Treatment of Acute Gout., 2012,, 121-130.		0
107	Gout: Update on Current Therapeutics. Current Treatment Options in Rheumatology, 2015, 1, 131-142.	1.4	0
108	Gouty Inflammation. , 2019, , 635-645.		0

#	Article	IF	CITATIONS
109	Nonpharmacologic Treatment of Gout. , 2019, , 155-161.		0
110	Imaging of gout., 2016,,.		0
111	Improvement in hepatic fibrosis estimated by Fibrosis-4 index in pegloticase treated chronic refractory gout patients Clinical and Experimental Rheumatology, 2022, , .	0.8	0